Why Catalent Stock Dropped Almost 25%

Order By

KEY POINTS The healthcare-solutions provider’s first-quarter earnings were below expectations. The company fell short of meeting...

Nov 2

by Stacy Brooks

KEY POINTS Gilead Sciences provided a piece of good news about a cancer treatment. It wasn’t...

Aug 16

by Stacy Brooks

KEY POINTS Several pharmaceutical stocks fell yesterday due to litigation linked to safety concerns with Zantac,...

Aug 12

by Stacy Brooks

KEY POINTS Gilead Sciences’ primary market, which focuses on HIV, is in good shape. The firm...

Aug 10

by Stacy Brooks

KEY POINTS: PHARMA STOCK BUYS Merck and AstraZeneca have strong product portfolios and pipelines. Expect annual...

Mar 21

by Stacy Brooks

KEY POINTS: CHEAP DIVIDEND STOCKS TO BUY IN MARCH Pfizer could be an even better value...

Mar 2

by Stacy Brooks